Biphenyl-dimethyl-dicarboxylate.
Each Hepapac soft capsule contains biphenyl-dimethyl dicarboxylate 3 mg.
Hepapac also contains the following excipients: Triacetin, polyethylene glycol 400, polyoxyl 40, hydrogenated castor oil, gelatine, concentrated glycerin, d-sorbitol solution, ethyl vanillin, carnauba wax, fractionated coconut oil.
Pharmacology: Protection of hepatocellulars against injuries, improves impaired liver function, promotes detoxification, restores liver mass and activates immunobiological response.
Support treatment of injury of liver cells caused by virus or chemical substances.
1 soft capsule 3 times daily. Dosage may be increased to 2 soft capsules 3 times daily if improvement is not shown after 2 months of therapy. Duration of therapy is usually 6-12 months.
Hypersensitivity to any of the ingredients of Hepapac.
Carefully administer Hepapac to patients with chronic active hepatitis and cirrhosis. There are few cases where patients decrease alanine transaminase (ALT) levels during therapy. After discontinuation of Hepapac, ALT levels may increase but re-administration may improve it.
Use in pregnancy & lactation: Caution should be observed when using Hepapac to pregnant and breastfeeding women.
Caution should be observed when using Hepapac to pregnant and breastfeeding women.
Administration of Hepapac may cause xerostomia and nausea. Skin rash may occur, however, this may disappear when using anti-allergic agents. Transient jaundice may occur, however, discontinuation or concomitant use of therapeutic agent for jaundice may eradicate the adverse reaction.
Abdominal distention may occur rarely but may also disappear immediately.
Concomitant use with inosine, recurrent elevation of ALT may improve.
Store in an air-tight container and at room temperature.
Shelf-Life: 36 months.
A05BA - Liver therapy ; Used in liver therapy.
Sign Out
